Effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with uncontrolled asthma

Allergology International

Volumn 61, Issue 2, 2012, Pages 323-329

  Akamatsu, Taisuke ^a   Shirai, Toshihiro ^b   Kato, Masato ^a   Hashimoto, Dai ^a   Yasui, Hideki ^a   Inui, Naoki ^a   Suda, Takafumi ^a   Yokomura, Koshi ^c   Hayakawa, Hiroshi ^d   Ide, Kyotaro ^e   Toyoshima, Mikio ^f   Kuroishi, Shigeki ^g   Yasuda, Kazumasa ^h   Suganuma, Hideki ⁱ   Yamada, Takashi ^j   Masuda, Masafumi ^j   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^d National Hospital Organization   (Japan)

^e Department of Respiratory Medicine   (Japan)

^f HAMAMATSU ROSAI HOSPITAL   (Japan)

^g Department of Respiratory Medicine   (Japan)

^h Iwata City Hospital   (Japan)

ⁱ Department of Orthopedic Surgery Shimada Municipal Hospital   (Japan)

^j SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

more..

Author keywords

Asthma Control Questionnaire; Combination therapy; Formoterol budesonide; Salmeterol fluticasone; Switching

Indexed keywords

ADOAIR; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FRACTIONAL EXHALED NITRIC OXIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PREDNISOLONE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SCORING SYSTEM; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84862664158     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.11-OA-0384     Document Type: Article

References (20)

1. Ohta K, Yamaguchi M, Akiyama K et al. Japanese guideline for adult asthma. Allergol Int 2011;60:115-45.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2010. Available at: http://www.ginasthma.org.
3. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29-34.
4. Tarsin W, Assi KH, Chrystyn H. In-vitro intra-and interinhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004;17:25-32.
5. Granlund KM, Asking L, Lindblad T et al. An in-vitro comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers. Eur Respir J 2000;16 (Suppl 31):455s.
6. Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006;100:1152-62.
7. Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide_ formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-36.
8. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99: 553-8.
9. Juniper E, Bousquet J, Abetz L, Bateman ED, The GOAL Committee. Identifying 'well-controlled' and 'not wellcontrolled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21.
10. The Committee of Pulmonary Physiology, Japanese Respiratory Society. [Guidelines for Pulmonary Function Tests. Spirometry, Flow-Volume Curve, Diffusing Capacity of the Lung]. Tokyo: The Japanese Respiratory Society, 2004(in Japanese).
11. Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respiratory Crit Care Med 1995;151:1320-5.
12. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
13. Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011;24:571-6.
14. American College of Chest Physicians. Aerosol consensus statement. Consensus conference on aerosol delivery. Chest 1991;100:1106-9.
15. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. H-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002;15:1353-8.
16. 2-adrenergic receptor agonists based on their intrinsic efficacy. Allergol Int 2005;54:89-97.
17. van der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004;17:89-95.
18. Connor RD, Patrick DL, Parasuraman B, Martin P, Goldman M. Comparison of patient-reported outcomes during treatment with adjustable-and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. J Asthma 2010; 47:217-23.
19. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003;111: 256-62.
20. Gelb AF, Taylor CF, Simmons M, Shinar C. Role of addon zileuton on total exhaled, large airway, and small airway /alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 μg/salmeterol 50 μg. Pulm Pharmacol Ther 2009;22:516-21.